TEVA vs. INCR

Last updated Apr 2, 2026

Compare and contrast key facts about Teva Pharmaceutical Industries Limited (TEVA) and INC Research Holdings Inc (INCR).

Performance

TEVA vs. INCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Teva Pharmaceutical Industries Limited (TEVA) and INC Research Holdings Inc (INCR). The values are adjusted to include any dividend payments, if applicable.

TEVA vs. INCR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TEVA Teva Pharmaceutical Industries Limited	-3.08%	41.61%	111.11%	14.47%	13.86%	-14.61%
INCR INC Research Holdings Inc	-15.01%	-42.77%	23.27%	-60.92%	-49.07%	-4.00%

Fundamentals

Market Cap TEVA : $35.48B INCR : $43.93M
EPS TEVA : $1.21 INCR : -$1.25
PS Ratio TEVA : 2.04 INCR : 0.18
PB Ratio TEVA : 4.48 INCR : 0.10
Total Revenue (TTM) TEVA : $17.26B INCR : $243.12M
Gross Profit (TTM) TEVA : $8.94B INCR : $40.61M
EBITDA (TTM) TEVA : $3.80B INCR : -$79.49M

Returns By Period

In the year-to-date period, TEVA achieves a -3.08% return, which is significantly higher than INCR's -15.01% return.

TEVA

• 1D: 0.43%
• 1M: -10.42%
• YTD: -3.08%
• 6M: 50.80%
• 1Y: 97.84%
• 3Y*: 50.64%
• 5Y*: 21.38%
• 10Y*: -5.21%

INCR

• 1D: 3.00%
• 1M: -8.97%
• YTD: -15.01%
• 6M: -53.13%
• 1Y: -43.55%
• 3Y*: -27.62%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TEVA vs. INCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TEVA

TEVA Risk / Return Rank: 92
TEVA Sharpe Ratio Rank: 93
TEVA Sortino Ratio Rank: 92
TEVA Omega Ratio Rank: 91
TEVA Calmar Ratio Rank: 92
TEVA Martin Ratio Rank: 92

INCR

INCR Risk / Return Rank: 8
INCR Sharpe Ratio Rank: 6
INCR Sortino Ratio Rank: 6
INCR Omega Ratio Rank: 9
INCR Calmar Ratio Rank: 13
INCR Martin Ratio Rank: 6

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TEVA vs. INCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and INC Research Holdings Inc (INCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TEVA	INCR	Difference
Sharpe ratio Return per unit of total volatility	2.33	-0.91	+3.24
Sortino ratio Return per unit of downside risk	3.11	-1.36	+4.47
Omega ratio Gain probability vs. loss probability	1.42	0.85	+0.57
Calmar ratio Return relative to maximum drawdown	4.44	-0.77	+5.22
Martin ratio Return relative to average drawdown	12.93	-1.63	+14.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TEVA vs. INCR - Sharpe Ratio Comparison

The current TEVA Sharpe Ratio is 2.33, which is higher than the INCR Sharpe Ratio of -0.91. The chart below compares the historical Sharpe Ratios of TEVA and INCR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TEVA	INCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.33	-0.91	+3.24
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.50	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.11	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.31	-0.59	+0.90

Correlation

The correlation between TEVA and INCR is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TEVA vs. INCR - Dividend Comparison

Neither TEVA nor INCR has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
TEVA Teva Pharmaceutical Industries Limited	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.88%	3.19%	1.77%
INCR INC Research Holdings Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

TEVA vs. INCR - Drawdown Comparison

The maximum TEVA drawdown since its inception was -90.89%, roughly equal to the maximum INCR drawdown of -91.57%. Use the drawdown chart below to compare losses from any high point for TEVA and INCR.

Drawdown Indicators

	TEVA	INCR	Difference
Max Drawdown Largest peak-to-trough decline	-90.89%	-91.57%	+0.68%
Max Drawdown (1Y) Largest decline over 1 year	-21.79%	-57.80%	+36.01%
Max Drawdown (5Y) Largest decline over 5 years	-43.70%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-88.71%	—	—
Current Drawdown Current decline from peak	-55.29%	-91.07%	+35.78%
Average Drawdown Average peak-to-trough decline	-31.90%	-64.44%	+32.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.49%	27.46%	-19.97%

Volatility

TEVA vs. INCR - Volatility Comparison

Teva Pharmaceutical Industries Limited (TEVA) has a higher volatility of 11.82% compared to INC Research Holdings Inc (INCR) at 8.73%. This indicates that TEVA's price experiences larger fluctuations and is considered to be riskier than INCR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TEVA	INCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.82%	8.73%	+3.09%
Volatility (6M) Calculated over the trailing 6-month period	27.30%	36.31%	-9.01%
Volatility (1Y) Calculated over the trailing 1-year period	42.20%	48.28%	-6.08%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	42.76%	64.35%	-21.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	47.20%	64.35%	-17.15%

Financials

TEVA vs. INCR - Profitability Comparison

The chart below illustrates the profitability comparison between Teva Pharmaceutical Industries Limited and INC Research Holdings Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TEVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 2.66B and revenue of 4.71B. Therefore, the gross margin over that period was 56.4%.

INCR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported a gross profit of 20.11M and revenue of 65.01M. Therefore, the gross margin over that period was 30.9%.

TEVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported an operating income of 1.27B and revenue of 4.71B, resulting in an operating margin of 26.9%.

INCR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported an operating income of 2.86M and revenue of 65.01M, resulting in an operating margin of 4.4%.

TEVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Teva Pharmaceutical Industries Limited reported a net income of 480.00M and revenue of 4.71B, resulting in a net margin of 10.2%.

INCR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, INC Research Holdings Inc reported a net income of -852.00K and revenue of 65.01M, resulting in a net margin of -1.3%.